Although colorectal cancer patients with MSI-H generally exhibit favorable responses to ICIs such as anti-PD-1, PD-L1, or CTLA-4 antibodies (56), emerging evidence has revealed critical modifying factors: 1. The gene discussed is CTLA4; the disease is colorectal cancer.